Incannex has received approval from Bellberry Human Research Ethics Committee (‘HREC’) to commence the bioavailability/bioequivalence (‘BA/BE’) clinical trial ...
Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway’s application to initiate CBL-514’s pivotal phase 3 study (CBL-0301 phase 3) for subcutaneous fat ...
The Bellberry application is a key regulatory milestone, advancing Adze's commitment to initiating clinical studies of its immunotherapy candidate, Adze1.C, Submitting the Bellberry HREC application ...
Adze Biotech, develops systemically-deliverable oncolytic immunotherapies, received Bellberry HREC approval for Phase I clinical trial in metastatic melanoma. This approval validates the robustness of ...
Bellberry is a leading independent ethics committee certified by the National Health and Medical Research Council (NHMRC) with the approval allowing LTR Pharma (ASX:LTP) to move forward with patient ...
MELBOURNE, Australia, July 06, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results